Fig. 4: Rapamycin inhibits lipid synthesis and tumorigenesis.
L-TKO mice were administrated with rapamycin (2.5 mg kg−1 d−1) or drug vehicle for 5 months. a H&E staining showed that rapamycin-treated L-TKO mice developed no tumor. b Hepatic TG and CHOL were determined. c Related hepatic mRNA (qPCR) from rapamycin or vehicle treated 10-month-old L-TKO mice (n = 6, **P < 0.01, ***P < 0.001). d Liver tissues were lysed and mTORC1 signal activity was determined by the high levels of pS6, lipid synthesis inhibition was determined by the low levels of SREBP1(m), ACC1 and FASN. e HepG2 cells treated with rapamycin (1.0 × 10−7 m) or drug vehicle for 24 h, and pS6, SREBP1(m), ACC1 and FASN were determined. Western blots were quantified. n ≥ 6, ***P < 0.001
